Asparaginase erwinia chrysanthemi Disease Interactions

The use of asparaginase Erwinia chrysanthemi is contraindicated in patients with a history of serious pancreatitis with prior L-asparaginase therapy. It is recommended to evaluate patients with symptoms compatible with pancreatitis to establish a diagnosis. In the case of mild pancreatitis, it is recommended to hold treatment until the signs and symptoms subside, and amylase levels return to normal. Discontinue treatment with this agent for severe or hemorrhagic pancreatitis manifested by abdominal pain >72 hours and amylase elevation of >= 2.0 x ULN.

Serious thrombotic events, including sagittal sinus thrombosis and pulmonary embolism have been reported with the use of Erwinia-derived L-asparaginase therapy. Its use is contraindicated in patients with history of serious thrombosis or hemorrhagic events with prior L-asparaginase therapy. It is recommended to exercise caution in patients predisposed to thrombotic or hemorrhagic events. It is recommended to discontinue asparaginase Erwinia chrysanthemi if thrombotic or hemorrhagic event occur until symptoms resolve.

The use of asparaginase Erwinia chrysanthemi has been associated with glucose intolerance. Exercise caution when using this agent in patients with diabetes. It is recommended to monitor glucose levels at the start of therapy, and periodically thereafter in all patients. Administer insulin therapy as necessary in patients with hyperglycemia.